CRSP
CRISPR Therapeutics AG
NASDAQ · Healthcare · Biotechnology · CH
$56.56
−1.33%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 80.68x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 3.13x
- Price / sales
- 408.37x
- Price / cash flow
- -11.43x
Enterprise value
- Enterprise value
- $3.9B
- EV / sales
- 290.35x
- EV / EBITDA
- -8.56x
- EV / EBIT
- -7.31x
- Market cap
- $5.5B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026